Table 1.
Qualitative characteristics of the included patients.
| Characteristics | Total (N = 130) | Without post COVID-19 sequelae (N = 103) | Post COVID-19 sequelae (N = 27) | p |
|---|---|---|---|---|
| Gender | ||||
| Male | 63 (48.5) | 46 (44.7%) | 17 (63.0%) | 0.090 |
| Female | 67 (51.5) | 57 (55.3%) | 10 (37.0%) | |
| Hypertension | 50 (38.5) | 36 (35.0%) | 14 (51.9%) | 0.108 |
| Diabetes mellitus | 13 (10.0) | 11 (10.7%) | 2 (7.4%) | 1.000 |
| Pulmonary disease (chronic obstructive pulmonary disease, asthma, other) | 21 (16.2) | 16 (15.5%) | 5 (18.4%) | 0.770 |
| Immunosuppression | 7 (5.4) | 5 (4.9%) | 2 (7.4%) | 0.635 |
| Obesity | 38 (29.2) | 28 (27.2%) | 10 (37.0%) | 0.347 |
| Smoking history | 60 (46.2) | 46 (44.7%) | 14 (51.9%) | 0.475 |
| Cough | 29 (22.3) | 25 (24.3%) | 4 (14.8%) | 0.299 |
| Dyspnea | 49 (37.7) | 37 (35.9%) | 12 (44.4%) | 0.394 |
| Asthenia | 48 (36.9) | 40 (38.8%) | 8 (29.6%) | 0.388 |
| Myalgias-arthralgias | 25 (19.2) | 20 (19.4%) | 5 (18.5%) | 0.930 |
| Anosmia-dysgeusia | 31 (23.8) | 25 (24.3%) | 6 (22.2%) | 0.839 |
| Memory loss | 14 (10.8) | 10 (9.7%) | 4 (14.8%) | 0.485 |
| Dermatological disorders | 12 (9.2) | 9 (8.7%) | 3 (11.1%) | 0.711 |
| Headache | 21 (16.2) | 17 (16.5%) | 4 (14.8%) | 1.000 |
| Visual loss | 7 (5.4) | 5 (4.9%) | 2 (7.4%) | 0.633 |
| Back low pain | 6 (4.6) | 4 (3.9%) | 2 (7.4%) | 0.603 |
| Crackles | 12 (9.2) | 8 (7.8%) | 4 (14.8%) | 0.274 |
The data are the number of cases and the percentage.